EQ 427 snags Series A

EG 427, a developer of pinpoint gene therapy, has secured 12 million euros in Series A funding.

EG 427, a developer of pinpoint gene therapy, has secured 12 million euros in Series A funding. David Lamond led the round in association with San Francisco-based large family offices.

Source: Press Release